GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
19 sept. 2023 09h00 HE
|
GeoVax, Inc.
Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
12 sept. 2023 09h00 HE
|
GeoVax, Inc.
Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
11 sept. 2023 09h00 HE
|
GeoVax, Inc.
Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
31 août 2023 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
29 août 2023 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Aug. 29, 2023 (GLOBE NEWSWIRE) --...
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
28 août 2023 09h00 HE
|
GeoVax, Inc.
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
10 août 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months via NewMediaWire — GeoVax Labs, Inc....
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
09 août 2023 16h00 HE
|
GeoVax, Inc.
Progress and Promising Outlook for Gedeptin® and GEO-CM04S1; Phase 2 GEO-CM04S1; Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia Company to Host Conference Call and Webcast...
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
26 juil. 2023 09h00 HE
|
GeoVax, Inc.
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Issuance of Ebola Vaccine Patent
24 juil. 2023 09h00 HE
|
GeoVax, Inc.
Addressing Multiple Strains of Ebolavirus ATLANTA, GA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...